Abiopharma

🔍 Jampol Thad (Executive)

Company: Intapp, Inc. (INTA)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Sold 23,800 shares of Common Stock at $40.7485 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 914,107.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,200 shares of Common Stock at $41.0 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 912,907.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 34,972.00 | Footnotes: F3

Footnotes:

• F1: The sale of shares of common stock of Intapp, Inc. was executed pursuant to a 10b5-1 plan put in place by the Reporting Person on December 15, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to Intapp, Inc., any security holder of Intapp, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
• F3: Shares held by the reporting person's spouse. The reporting person disclaims beneficial ownership of the securities owned by his spouse, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.